Introduction
The term myofibrillar myopathies (MFMs) was proposed in 1996 as a noncommittal designation for a group of chronic neuromuscular diseases associated with common morphologic features [1, 2] . These consist of a distinct pathologic pattern of myofibrillar disorganization that begins at the Z-disk and is followed by accumulation of myofibrillar degradation products and ectopic expression of diverse proteins that include desmin, aB-crystallin ( Fig. 1c) , dystrophin ( Fig. 1d) , myotilin, sarcoglycans, neural cell adhesion molecule (NCAM), plectin, gelsolin, ubiquitin, filamin C, Xin, and congophilic amyloid material [3] [4] [5] [6] [7] . The diagnosis of MFM is established by muscle biopsy. In trichrome-stained sections of diseased muscle, the abnormal fibers show an admixture of amorphous, granular, or hyaline deposits that vary in shape and size ( Fig. 1a ). Many abnormal fiber regions, and especially the hyaline structures, either are devoid of or have diminished oxidative enzyme activity (Fig. 1b) . Some hyaline structures are intensely congophilic and some muscle fibers harbor small vacuoles containing membranous material. Electron microscopy shows that disintegration of the myofibrils begins at the Z-disk. This is followed by accumulation of degraded filamentous material in various patterns, aggregation of membranous organelles and glycogen in spaces vacated by myofibrils, and degradation of dislocated membranous organelles in autophagic vacuoles.
The clinical features of MFMs are somewhat more variable, but these disorders are transmitted by autosomal dominant inheritance, distal muscles are often involved, and cardiomyopathy and peripheral neuropathy are frequent associated features. Electromyogram (EMG) studies of affected muscles reveal myopathic motor unit potentials and abnormal electrical irritability, often with myotonic discharges.
In the past decade, several disease genes in MFMs have been identified, but in more than half of the patients the molecular defects are unknown.
Purpose of review
The aim of this communication is to provide an up-to-date overview of myofibrillar myopathies.
Recent findings
The most important recent advance in the myofibrillar myopathies has been the discovery that mutations in Z band alternatively spliced PDZ-containing protein and filamin C, as well as in desmin, aB-crystallin and myotilin, result in similar pathologic alterations in skeletal muscle that are typical of myofibrillar myopathy. Despite the increasing genetic heterogeneity, the clinical and morphologic phenotypes are remarkably homogeneous. The typical clinical manifestation is slowly progressive proximal, distal or both proximal and distal limb muscle weakness. Cardiomyopathy can be associated and is sometimes the presenting finding. Peripheral neuropathy also occurs in some patients. In every myofibrillar myopathy, there is abnormal accumulation of an array of proteins at ectopic sites as well as accumulation of degraded myofibrillar proteins forming large aggregates. The key issue now is to analyze the molecular mechanisms underlying the cascade of events that destroy the myofibrillar architecture and trigger the aberrant expression of multiple proteins. Summary Several disease genes have recently been recognized in myofibrillar myopathies. So far, the disease proteins identified are components of or chaperone for the Z-disk. In each case, the molecular defect leads to a stereotyped cascade of structural events in the muscle fiber. 
Desminopathy subset of myofibrillar myopathy
The desminopathy patients reported to date are similar to other MFM patients in distribution of weakness, serum creatine kinase level, and EMG findings. The age of onset is between 10 and 61 years. The distribution of weakness is distal or both proximal and distal. Muscle atrophy, mild facial weakness, dysphagia, dysarthria, and respiratory insufficiency can occur. Serum creatine kinase levels are normal or mildly elevated. EMG studies usually show myopathic motor unit potentials and abnormal electrical irritability, including myotonic discharges. Cardiomyopathy, especially of the arrhythmogenic type, is a common manifestation. The family history is consistent with dominant inheritance, and only rarely with recessive inheritance. Some cases are sporadic [4, 8] .
Since the first description of mutations in the gene encoding desmin (DES) by Goldfarb et al. [9] and Munoz-Marmol et al. [10] , more than 40 mutations have been reported (see Fig. 2 ). The scapuloperoneal syndrome of Kaeser has now been traced to an autosomal dominant mutation in DES in a large kinship [11] .
Some desmin mutants fail to assemble into filaments in vitro, but others demonstrate normal filament assembly [9, 12, 13] . As the combined expression of mutant and wild-type desmin can produce morphologically normal filaments, it has been suggested that desmin mutations cause subtle age-dependent structural alterations of intermediate filament assembly that eventually lead to disease [14] . Recently, Shinde et al. [15] showed abnormal cytoplasmic reactivity for caveolin-3 and aggregates of vesicular and tubular structures in a patient with desminopathy. This led them to hypothesize that the accumulation of multiple proteins could be partially due to impaired cellular trafficking, as caveolae are normally transported from Golgi complex to the surface membrane. However, caveolin could be yet another nonspecifically overexpressed protein, like dystrophin.
aB-crystallinopathy subset of myofibrillar myopathy
In 1998, a heterozygous missense mutation (Arg120Gly) in aB-crystallin was identified by Vicart et al. [16] in a previously reported French kinship. Subsequently, two heterozygous truncating mutations were observed in two patients in the Mayo Clinic MFM cohort [17] . Affected patients present in adult life, have symmetric proximal and distal muscle weakness and atrophy, and respiratory involvement. Some patients also have hypertrophic cardiomyopathy, palatopharyngeal weakness, and cataracts.
Transgenic mice with cardiac-specific expression of Arg120Gly aB-crystallin develop cardiomyopathy in 3 months and die of heart failure at 6-7 months [18] . Interestingly, exercise in these mice delays the appearance of heart failure and prolongs survival. A possible explanation is that exercise decreases the accumulation of the preamyloid oligomers, which are potent mediators of cytotoxicity in protein-misfolding neurodegenerative diseases. [19] In agreement with this concept, when mutant aB-crystallin is transfected into COS (African green monkey kidney fibroblast) cells, it produces cytoplasmic aggregates, and the degree of phosphorylation is higher in the expressed mutant than in the wild-type protein [20] . Moreover, mutant proteins interact abnormally with both wild-type and mutant aB-crystallins, as well as with other small heat shock proteins.
Myotilinopathy subset of myofibrillar myopathy
In 2000, a Thr57Ile mutation in the gene encoding myotilin (MYOT) was detected in a large kinship that had previously been linked to the myotilin locus at 5q31 [21] . The disease was labeled as limb-girdle muscular dystrophy 1A (LGMD1A). In this kinship, proximal leg and arm muscle weakness appeared in the third decade of life; distal muscle weakness became apparent later in the course of the disease. Tight heel cords and a nasal dysarthric speech were frequently observed. The serum creatine kinase level could be normal or up to 15-fold elevated. Some patients had hypoactive tendon reflexes. Two years later, a second kinship with a similar phenotype was found to have a Ser55Phe mutation in MYOT [22] . One study [22] , however, did not assess the histopathologic features of the disease, and the other [21] documented only Z-disk alteration in some muscle fibers.
Subsequently, six new myotilin mutations were identified in eight unrelated patients of the Mayo Clinic MFM cohort [3] , indicating that the pathology of LGMD1A is MFM. The mean age of onset was 60 years and in three patients the weakness was more prominent distally than proximally. Three patients also had cardiac involvement without signs of coronary artery disease. Peripheral neuropathy, based on clinical, EMG, histologic, or combined criteria, was apparent in all patients. Subsequent studies by other investigators identified additional patients with mutations in myotilin, including members of a kinship originally described under the rubric of 'spheroid body myopathy' [6, [23] [24] [25] . These patients also had progressive weakness of proximal and distal limb muscles, dysarthric, nasal speech, hypoactive tendon reflexes, and respiratory failure. Dominant inheritance, cardiomyopathy and intrafamiliar phenotypic variability were present in some kinships.
All myotilin mutations reported to date are heterozygous missense amino acid changes, and all but one mutation fall in MYOT exon 2 [3, 6, [21] [22] [23] [24] 26] .
Targeted deletion of myotilin in mice does not lead to obvious abnormalities and both muscle morphology and strength are normal [27] . In contrast, transgenic mice expressing a disease-causing mutant myotilin, Thr57Ile, reproduce the morphological and functional features of human myotilinopathy, and the morphologic changes become progressively larger and more numerous with age [28] . Interestingly, double-transgenic mice expressing both wild-type and Thr57Ile myotilin exhibit significantly more severe muscle degeneration and earlier onset of muscle weakness than single Thr57Ile transgenic mice [29] . This observation suggests that the presence of the wild-type myotilin protein enhances the disease process.
In addition to the accumulation of the proteins listed above, there is now good evidence that the following proteins accumulate abnormally in myotilinopathy and desminopathy muscle specimens: phospho-tau, actin, amyloid b, clusterin [6] , a mutant nonfunctional ubiquitin, p62, a multimeric signal protein [30] , glycoxidation and lipoxidation markers, neuronal, inducible and endothelial nitric oxide synthases, and superoxide dismutase [31] . Moreover, there was aberrant increase of neuronrelated proteins such as ubiquitin carboxyterminal hydrolase L1, synaptosomal-associated protein 25, synaptophysin, and a-internexin. The latter findings are attributed to decreased activity of the neuron-restrictive silencer factor (NRSF) and RE1 silencing transcription factor (REST), a transcription factor expressed in nonneuronal tissues that inhibits the expression of several neuronal genes [32 ] .
Zaspopathy subset of myofibrillar myopathy
Zaspopathy was first described by Selcen and Engel [5] in 11 MFM patients who carried heterozygous missense mutations in ZASP. The mean age of onset was in the sixth decade. Most patients presented with muscle weak-ness but one, whose father also had muscle weakness, presented with palpitations and mild hypercreatine kinasemia. Seven out of 11 patients had family history consistent with autosomal dominant inheritance. In five patients, the weakness was more prominent distally than proximally and it was only distal in one patient. Two patients had only proximal muscle weakness. The three remaining patients had both proximal and distal weakness. Three patients had cardiac involvement without signs of coronary artery disease and in one of these the cardiac symptoms antedated the muscle weakness by 10 years. Peripheral nerve involvement by clinical, EMG, or histologic criteria was detected in five patients.
The mutations detected by Selcen and Engel [5] were Ala147Thr and Ala165Val in exon 6, and Arg268Cys in exon 9. The Ala165Val mutation is within, and the Ala147Thr mutation immediately before the ZASP-like motif needed for interaction with a-actinin [33] .
Later, a large kinship originally described by Markesbery et al. [34] as well as five other families with distal myopathy and histopathologic features of MFM were shown to carry the same Ala165Val mutation. These six kinships with zaspopathy and the three patients carrying this mutation observed at the Mayo Clinic may have a common founder [35 ] .
Filaminopathy subset of myofibrillar myopathy
In 2005, a dominant Trp2710X mutation in the last exon of the filamin C gene (FLNC) was detected in 17 affected members of a large German kinship by Vorgerd et al. [7] . Eight patients presented between 37 and 57 years of age with slowly progressive distal leg weakness. The serum creatine kinase level was elevated up to eight-fold. Four patients had signs of respiratory insufficiency, one had an incomplete right bundle branch block, and three also had signs of peripheral neuropathy. Recently, two additional German families with the same nonsense mutation in FLNC were reported and all three families may have a common founder [36] . Subsequently, three MFM kinships carrying the same mutation were identified in the Mayo Clinic MFM cohort. Age at onset and clinical presentation were similar to those reported by Vorgerd et al. [7] .
Experimental studies have shown that the dimerization domain of the mutant filamin C is less stable and more susceptible to proteolysis than the same wild-type domain. As a consequence, the mutant protein does not dimerize properly and forms aggregates in vitro and in cultured cells [7, 37] . Mice carrying a deletion of the last eight FLNC exons have severely reduced birth weights, reduced number of muscle fibers and primary myotubes, and die shortly after birth due to respiratory failure [38] . These data emphasize the important role of filamin C in muscle development.
Conclusion
The fact that the initial pathologic change in MFMs is centered on the Z-disk explains the nearly stereotypic pathologic features and enables a candidate gene approach. So far, all MFM mutations occur in proteins that are either components of the Z-disk or help to maintain its structure. One can confidentially predict that further studies will uncover other MFM disease genes. A major unsolved issue is regarding the signaling mechanism between the Z-disk and the nucleus that results in abnormal transcription, translation, or both, of multiple genes.
